Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

Limited Presence of IL-22 Binding Protein, a Natural IL-22 Inhibitor, Strengthens Psoriatic Skin Inflammation

(2017) Jérôme C. Martin et al.   JOURNAL OF IMMUNOLOGY

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets

(2016) Giulia Merlo et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Successful response in a case of severe pustular psoriasis after interleukin-1β inhibition

(2016) P. Skendros et al.   BRITISH JOURNAL OF DERMATOLOGY

Bone remodeling in psoriasis and psoriatic arthritis

(2016) Ananta Paine et al.   CURRENT OPINION IN RHEUMATOLOGY

Health state utility, willingness to pay, and quality of life among Taiwanese patients with psoriasis

(2016) Wei-Chih Ko et al.   Dermatologica Sinica

A revolutionary therapeutic approach for psoriasis: bispecific biological agents

(2016) T. Torres et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

IL-35 Decelerates the Inflammatory Process by Regulating Inflammatory Cytokine Secretion and M1/M2 Macrophage Ratio in Psoriasis

(2016) Junfeng Zhang et al.   JOURNAL OF IMMUNOLOGY

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

(2016) Peter C.M. van de Kerkhof et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Assessment of Interleukin 16 Serum Levels and Skin Expression in Psoriasis Patients in Correlation with Clinical Severity of the Disease

(2016) Dorota Purzycka-Bohdan et al.   PLoS One

Are interleukin-15 and -22 a new pathogenic factor in pustular palmoplantar psoriasis?

(2016) Aleksandra Lesiak et al.   Postepy Dermatologii i Alergologii

Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)

(2015) D. Thaçi et al.   BRITISH JOURNAL OF DERMATOLOGY

Treatment of two patients with generalized pustular psoriasis with the interleukin-1β inhibitor gevokizumab

(2015) B. Mansouri et al.   BRITISH JOURNAL OF DERMATOLOGY

Palmoplantar pustular psoriasis unresponsive to the interleukin-1β antagonist canakinumab

(2015) B. Mansouri et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Serum IL-33 levels are increased in patients with psoriasis

(2015) A. Mitsui et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

(2015) Diamant Thaçi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)

(2015) Ulrich Mrowietz et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

(2015) Ian Landells et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Role of IL-38 and Its Related Cytokines in Inflammation

(2015) Xianli Yuan et al.   MEDIATORS OF INFLAMMATION

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Atherosclerosis in psoriatic disease: latest evidence and clinical implications

(2015) Lihi Eder et al.   Therapeutic Advances in Musculoskeletal Disease

First-In-Human, Phase 1, Randomized, Dose-Escalation Trial with Recombinant Anti–IL-20 Monoclonal Antibody in Patients with Psoriasis

(2015) Alice B. Gottlieb et al.   PLoS One

A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab

(2014) P. Jayasekera et al.   BRITISH JOURNAL OF DERMATOLOGY

Partial clinical response to anakinra in severe palmoplantar pustular psoriasis

(2014) M. Tauber et al.   BRITISH JOURNAL OF DERMATOLOGY

Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)

(2014) A. Blauvelt et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy of tocilizumab in a patient with refractory psoriatic arthritis

(2014) Luisa Costa et al.   CLINICAL RHEUMATOLOGY

The economic burden of psoriatic diseases in Taiwan

(2014) Kuan-Chen Chen et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

The IL-1 Family Member 7b Translocates to the Nucleus and Down-Regulates Proinflammatory Cytokines

(2014) S. Sharma et al.   JOURNAL OF IMMUNOLOGY

IL-19 Is a Component of the Pathogenetic IL-23/IL-17 Cascade in Psoriasis

(2014) Ellen Witte et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab

(2013) A Gedebjerg et al.   ACTA DERMATO-VENEREOLOGICA

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

(2013) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Is it relevant to use an interleukin-1-inhibiting strategy for the treatment of patients with deficiency of interleukin-36 receptor antagonist?

(2013) M. Tauber et al.   BRITISH JOURNAL OF DERMATOLOGY

Serum Cytokines Correlated with The Disease Severity of Generalized Pustular Psoriasis

(2013) Masaaki Yamamoto et al.   DISEASE MARKERS

Tumor Necrosis Factor Receptor Signaling in Keratinocytes Triggers Interleukin-24-Dependent Psoriasis-like Skin Inflammation in Mice

(2013) Snehlata Kumari et al.   IMMUNITY

Psoriasis onset with tocilizumab

(2013) Anne Grasland et al.   JOINT BONE SPINE

Therapeutic opportunities of the IL-22–IL-22R1 system

(2013) Robert Sabat et al.   NATURE REVIEWS DRUG DISCOVERY

Involvement of IL-9 in Th17-Associated Inflammation and Angiogenesis of Psoriasis

(2013) Tej Pratap Singh et al.   PLoS One

Successful use of tocilizumab in a patient with psoriatic arthritis

(2013) M. Hughes et al.   RHEUMATOLOGY

Interleukin 35: A Key Mediator of Suppression and the Propagation of Infectious Tolerance

(2013) Brian M. Olson et al.   Frontiers in Immunology

Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis

(2012) Z. He et al.   BRITISH JOURNAL OF DERMATOLOGY

Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24

(2012) F. Wang et al.   BRITISH JOURNAL OF DERMATOLOGY

T helper type 17 in psoriasis: From basic immunology to clinical practice

(2012) Hsien-Yi Chiu et al.   Dermatologica Sinica

IL-33 is secreted by psoriatic keratinocytes and induces pro-inflammatory cytokines via keratinocyte and mast cell activation

(2012) Anna Balato et al.   EXPERIMENTAL DERMATOLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis

(2012) Javier Rueda-Gotor et al.   JOINT BONE SPINE

Tumor Necrosis Factor-associated Palmoplantar Pustular Psoriasis Treated with Interleukin 6 Blocker

(2012) S. YOUNIS et al.   JOURNAL OF RHEUMATOLOGY

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study

(2012) A.B. Kimball et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Heterogeneity of Inflammatory and Cytokine Networks in Chronic Plaque Psoriasis

(2012) William R. Swindell et al.   PLoS One

IL-35 Is a Novel Responsive Anti-inflammatory Cytokine — A New System of Categorizing Anti-inflammatory Cytokines

(2012) Xinyuan Li et al.   PLoS One

Interleukin-18 expression and the response to treatment in patients with psoriasis

(2011) Hanaa Rasmy Mohamed Attia et al.   Archives of Medical Science

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) B.E. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

Interleukin (IL)-17 versus IL-27: opposite effects on tumor necrosis factor-α-mediated chemokine production in human keratinocytes

(2011) Susumu Fujiwara et al.   EXPERIMENTAL DERMATOLOGY

Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events

(2011) Caitriona Ryan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

(2011) Slaheddine Marrakchi et al.   NEW ENGLAND JOURNAL OF MEDICINE

A 52-Week Trial Comparing Briakinumab with Methotrexate in Patients with Psoriasis

(2011) Kristian Reich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased IL-23 Expression in Palmoplantar Psoriasis and Hyperkeratotic Hand Dermatitis

(2010) Joseph V. Lillis et al.   ARCHIVES OF DERMATOLOGY

Long-term control of refractory Schnitzler syndrome with anakinra: a case report

(2010) Hsien-Yi Chiu et al.   Dermatologica Sinica

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

Possible Roles of IL-27 in the Pathogenesis of Psoriasis

(2009) Sayaka Shibata et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-γ are not

(2009) Kerstin Wolk et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis

(2009) Roberta Caruso et al.   NATURE MEDICINE

IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells

(2009) W. Elyaman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

(2008) Alexa B. Kimball   ARCHIVES OF DERMATOLOGY

New-onset psoriasis following treatment with the interleukin-1 receptor antagonist anakinra

(2008) M.A. González-López et al.   BRITISH JOURNAL OF DERMATOLOGY

Differential regulation of interleukin 12 and interleukin 23 production in human dendritic cells

(2008) Franca Gerosa et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

IL-21 and TGF-β are required for differentiation of human TH17 cells

(2008) Li Yang et al.   NATURE